

Product References

Poietics® Osteoclast Precursor Cells

1. Iida R, Yasuda T, Kishi K. Identification of novel fibronectin fragments detected specifically in juvenile urine. *FEBS J.* 2007 Aug;274(15):3939-47.
2. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Hsueh Y-C, Rissanen J, Alatalo SL, Halleen JM, Yam LT. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. *Soc for Leukocyte Biol.* 2005; 77: 1-10.
3. La VD, Tanabe S, Grenier D. Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption. *J Periodontol Res.* 2009 Apr;44(2):193-8.
4. *Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. *J Orthop Res.* 2005 Jan; 23(1): 203-9.
5. Muhonen P, Avnet S, Parthasarathy RN, Janckila AJ, Halleen JM, Laitala-Leinonen T, Väänänen HK. Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules. *Biochem Biophys Res Commun.* 2007 Aug 10;359(4):889-95.
6. Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. *Exp Cell Res.* 2006 Jun 10;312(10):1909-23.
7. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R, Pinto A. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. *Endocr Relat Cancer.* 2005 Jun;12(2):471-82.
8. *Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation. *Biochem Biophys Res Comm.* 2004 Dec; 235(4): 1472-80.
9. Riihonen R, Supuran CT, Parkkila S, Pastorekova S, Väänänen HK, Laitala-Leinonen T. Membrane-bound carbonic anhydrases in osteoclasts. *Bone.* 2007 Apr;40(4):1021-31.
10. Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. *Calcif Tissue Int.* 2008 Feb;82(2):108-15.
11. Rissanen JP, Ylipahkala H, Fagerlund KM, Long C, Väänänen HK, Halleen JM. Improved methods for testing antiresorptive compounds in human osteoclast cultures. *J Bone Miner Metab.* 2009;27(1):105-9.
12. Rochet N, Balaguer T, Boukhechba F, Laugier JP, Quincey D, Goncalves S, Carle GF. Differentiation and activity of human preosteoclasts on chitosan enriched calcium phosphate cement. *Biomaterials.* 2009 Sep;30(26):4260-7. Epub 2009 May 23.
13. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. *FASEB J.* 2008 Feb 6. [Epub ahead of print]

14. Stein NC, Kreutzmann C, Zimmermann SP, Niebergall U, Hellmeyer L, Goettsch C, Schoppet M, Hofbauer LC. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. *J Bone Miner Res.* 2008 May;23(5):750-8.
15. Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. *BMC Endocr Disord.* 2009 Mar 30;9:10.
16. Taniguchi N, Yoshida K, Ito T, Tsuda M, Mishima Y, Furumatsu T, Ronfani L, Abeyama K, Kawahara K, Komiya S, Maruyama I, Lotz M, Bianchi ME, Asahara H. Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. *Mol Cell Biol.* 2007 Aug;27(16):5650-63.
17. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP agonist. *Embo J.* 2003 Dec 1; 22(23): 6267-76.
18. *Wu X, Pan G, McKenna MA, Zayzafoon M, Xiong WC, McDonald JM. RANKL regulates fas expression and fas-mediated apoptosis in osteoclasts. *J Bone Miner Res.* 2005 Jan; 20(1): 107-16.
19. *Yogesha SD, Khapli SM, Wani MR. Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor-alpha-induced osteoclast differentiation by down-regulation of THFR1 and TNFR2 expression. *J Biol Chem.* 2005.
20. *Zhang X, Aubin JE, Kim TH, Payne U, Chiu B, Inman RD. Synovial fibroblasts infected with salmonella enterica serovar typhimurium mediate osteoclast differentiation and activation. *Infect Immunol.* 2004 Dec; 72(12): 7183-9.

* References not specifically citing the use of Lonza cells, media, or reagents in their research.

+ Denotes sections containing only the articles published within the last ten years.